Lotronex (Alosetron Hydrochloride)
Brand Names: Lotronex
Methodology & AI Transparency ⓘ
Lotronex (Alosetron Hydrochloride) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Lotronex is a prescription brand-name serotonin-3 receptor antagonist product delivering active moiety Alosetron Hydrochloride (cross-referenced at /meds/alosetron-hydrochloride), registered by Sebela Pharmaceuticals Inc.
- 2 Real-world patient consensus: Lotronex links directly to generic Alosetron Hydrochloride (/meds/alosetron-hydrochloride) under FDA SPL 2026-06-30 (NDC 54766-894).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $30.28 wholesale mail-order against $80.24 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Lotronex (Alosetron Hydrochloride): nausea (12.2%), diarrhea (9.5%), constipation (6.7%).
Ask our AI Specialists anything about Lotronex (Alosetron Hydrochloride)
Lotronex (Alosetron Hydrochloride) Mechanism, CYP450 Pathways & DailyMed Monograph
Lotronex is a prescription brand-name serotonin-3 receptor antagonist product delivering active moiety Alosetron Hydrochloride (cross-referenced at /meds/alosetron-hydrochloride), registered by Sebela Pharmaceuticals Inc. under NDC 54766-894, 54766-895. Updated in FDA DailyMed SPL on 2026-06-30, this branded presentation (.5 mg/1 Tablet; 1 mg/1 Tablet) supports 1 Indications and usage lotronex: is indicated only for women with severe diarrhea-predominant irritable bowel syndrome.
Pharmacologically, Lotronex derives its clinical activity from Alosetron Hydrochloride, a serotonin-3 receptor antagonist molecule involving CYP3A4/CYP2C9 clearance pathways. Branded finished-dosage manufacturing (.5 mg/1 Tablet; 1 mg/1 Tablet; registered by Sebela Pharmaceuticals Inc.) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Alosetron Hydrochloride (CMS NADAC $2.5631/unit vs. $80.24 retail).
Pharmacokinetic profiling of Lotronex (Alosetron Hydrochloride) demonstrates an elimination half-life of Biphasic clearance with 8–21 hr terminal t½ under Lotronex (Alosetron Hydrochloride) maintenance with Systemic oral bioavailability of roughly 57%–69% following first-pass transit systemic bioavailability; clearance proceeds via primary cyp3a4 & cyp2c9 cytochrome processing paired with glucuronide elimination for lotronex (alosetron hydrochloride), reaching clinical onset within initial pharmacodynamic onset within 1–3 hrs (peak cmax) for lotronex (alosetron hydrochloride).
Titration schedules for Lotronex (Alosetron Hydrochloride) (.5 mg/1 Tablet → 1 mg/1 Tablet → 0.5mg Tablet) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to alosetron hydrochloride or lotronex (alosetron hydrochloride) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-06-30 lotronex (alosetron hydrochloride) spl; real-world patient logs highlight nausea (12.2% of reports), diarrhea (9.5% of reports), headache (8.3% of reports) alongside a 79.00% Worth-It consensus.
Potent CYP3A4 modulators alter hepatic clearance of Lotronex (Alosetron Hydrochloride), shifting steady-state plasma concentrations.
Avoid overlapping serotonin-3 receptor antagonist prescriptions alongside Lotronex (Alosetron Hydrochloride) to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Alosetron Hydrochloride or Lotronex (Alosetron Hydrochloride) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-06-30 Lotronex (Alosetron Hydrochloride) SPL
Logged Side-Effect Incidence (22 Reports)
Lotronex (Alosetron Hydrochloride) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lotronex (Alosetron Hydrochloride))
Human clinical trial evidence for Lotronex (Alosetron Hydrochloride) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Lotronex (Alosetron Hydrochloride) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.5631/unit (~$76.89/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $30.28 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $80.24 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $34.82 / mo | View logs ↓ |
Lotronex (Alosetron Hydrochloride) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Lotronex (Alosetron Hydrochloride) RxNorm Concept ID | 261362 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.5631 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $80.24 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $30.28 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 79.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Lotronex (Alosetron Hydrochloride) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Lotronex (Alosetron Hydrochloride) (serotonin-3 receptor antagonist) monograph synthesizing RxNorm 261362, openFDA FAERS signals, and $30.28–$80.24 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Lotronex (Alosetron Hydrochloride) community threads and patient logs by age, biological sex, dosage, and treatment duration.